Betta Pharmaceuticals Co., Ltd.

Angel Pharmaceuticals received IND approval from China's NMPA to initiate a Phase 1b/2 clinical trial of soquelitinib for moderate-to-severe atopic dermatitis treatment.

• C4 Therapeutics is set to advance clinical development of cemsidomide, with Phase 1 data expected in late 2025 for multiple myeloma and non-Hodgkin’s lymphoma. • CFT1946, targeting BRAF V600 mutations in solid tumors, is progressing through Phase 1, with data readouts anticipated in the second half of 2025. • Phase 1 data from CFT8919, aimed at EGFR L858R-mutated non-small cell lung cancer, will inform future development plans outside of China. • C4 Therapeutics' cash runway is projected to fund operations into 2027, supporting ongoing research and clinical programs.

EyePoint Pharmaceuticals reported positive interim results from its Phase 2 VERONA trial of DURAVYU for diabetic macular edema (DME).